Home › Compare › BDDDY vs ABBV
BDDDY yields 2.20% · ABBV yields 3.06%● Live data
📍 BDDDY pulled ahead of the other in Year 4
Combined, BDDDY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BDDDY + ABBV for your $10,000?
Bid Corporation Limited provides foodservice solutions worldwide. The company distributes fresh ingredients, including fish, seafood, meat, produce, dairy products, and ambient goods for the hospitality, institutional, catering, and retail sectors. It also provides foodservice and beverage distribution services for the HoReCa sector; and develops e-commerce solutions. In addition, the company manufactures and distributes meat, poultry, dairy, and general food ingredients, as well as baking ingredients and equipment; and offers a multi-temperature foodservice for various ambient, and chilled and frozen food products. Further, it distributes specialty products for the western styled food market; and frozen, chilled, and ambient local products for the independent street market, as well as sells non-food catering requirements and equipment. Bid Corporation Limited was founded in 1988 and is headquartered in Johannesburg, South Africa.
Full BDDDY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.